The combination of Cisplatin and S-1 (CS) achieved a response rate of approximately 45% with
the PFS being around 6 months and overall survival time being 13 months in Japanese and
Chinese gastric patients. It remains unclear whether the addition of docetaxel to CS would
further enhance the efficacy as it dose in DCF(docetaxel, cisplatin and 5-fluorouracil). This
is a single center, phase II clinical trial to evaluate the efficacy of docetaxel, cisplatin
and S-1 (DCS) as first line chemotherapy for patients with advanced gastric and
gastroesophageal junction cancer.